Current Oncology Reports

, Volume 12, Issue 5, pp 335–348

Molecular Testing in Lung Cancer: The Time Is Now

Authors

  • Haiying Cheng
    • Division of Hematology/Oncology, New York Presbyterian HospitalColumbia University Medical Center
  • Xunhai Xu
    • Division of Hematology/Oncology, New York Presbyterian HospitalColumbia University Medical Center
  • Daniel B. Costa
    • Division of Hematology/OncologyBeth Israel Deaconess Medical Center
  • Charles A. Powell
    • Division of Pulmonary and Critical Care Medicine, New York Presbyterian HospitalColumbia University Medical Center
    • Division of Hematology/Oncology, New York Presbyterian HospitalColumbia University Medical Center
Article

DOI: 10.1007/s11912-010-0118-z

Cite this article as:
Cheng, H., Xu, X., Costa, D.B. et al. Curr Oncol Rep (2010) 12: 335. doi:10.1007/s11912-010-0118-z

Abstract

In the past few years, we have witnessed a revolution in the molecular understanding of non-small cell lung cancer. Major progress has also been made in the clinic, with the introduction of EGFR-targeted and anti-angiogenic therapies. These advances have led to the development of a multitude of commercially available prognostic and predictive biomarkers. In particular, EGFR mutation and EML4/ALK testing have reached clinical validation and are incorporated into current treatment paradigms. This overview will present the scientific background of the biology of the relevant biomarkers and the studies conducted for their clinical validation. The technical challenges and shortcomings of these assays are also discussed. Furthermore, ongoing biomarker-driven clinical studies and the appropriate clinical use of available tests will be reviewed to assist the clinician with the proper incorporation of molecular testing into the routine care of patients with non-small cell lung cancer.

Keywords

Non-small cell lung cancerBiomarkersMolecular testingEGFRKRASEML4/ALK translocation

Copyright information

© Springer Science+Business Media, LLC 2010